{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:49:01Z","timestamp":1792511341543,"version":"4.5.0"},"reference-count":263,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Psilocybin has received increased attention as a potential therapeutic intervention, but it is unclear whether news media reporting reflects the strengths and limitations of the clinical trial evidence.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To describe the annual counts of published clinical trials of therapeutic psilocybin and contemporaneous media articles and compare tone, efficacy, and safety messaging.<\/jats:p>\n <\/jats:sec>\n \n Evidence Review<\/jats:title>\n This systematic review included English-language randomized and nonrandomized trials of psilocybin for clinical indications published from January 1, 2014, to October 10, 2024, and media articles describing its clinical use published from January 1, 2014, to April 22, 2025. Trials were found by searching Medline, Embase, PsycInfo, and the Cochrane Central Register of Controlled Trials (CENTRAL) and were characterized by design, indication, use of psychotherapy, and reporting of efficacy and safety. Media articles were found through the Factiva database and were characterized by audience, tone, indication, efficacy claim, and safety content. Data were extracted by 2 reviewers. Risk of bias for randomized clinical trials was assessed descriptively using the Cochrane Risk of Bias tool.<\/jats:p>\n <\/jats:sec>\n \n Findings<\/jats:title>\n Annual counts of both published clinical trials (n\u2009=\u200970) and media reports (n\u2009=\u2009172) increased from 2018 onward. Depression was the most common clinical indication in trials (47 [67%]) and media articles (138 [80%]), while media articles frequently referenced posttraumatic stress disorder (PTSD) (74 [43%]) and anxiety (72 [42%]) as clinical indications despite absent and limited trial evidence, respectively, for these conditions. Overall, 49 trials (70%) reported benefit for the primary indication; 125 media articles (73%) made at least 1 positive efficacy claim, and 122 (71%) adopted a favorable tone. Trials typically described small sample sizes of less than 100 participants (65 trials [93%]) and methodologic limitations. Overall, 31 trials (44%) reported safety outcomes, with some (24 [34%]) documenting short-term adverse events, such as transient anxiety, nausea, or headache; long-term safety was rarely assessed (4 trials [6%]). Only 51 media articles (30%) mentioned safety; when harms were discussed, potential long-term psychological risks were sometimes noted (12 articles [7%]).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this systematic review of clinical trials and media articles, both reported positive effects of therapeutic psilocybin with similar frequency. Academic publications were more cautious and explicit about methodologic limitations, whereas media reports often presented benefits as established, extrapolated them to indications with little or no trial evidence, and provided less safety information. Clarifying these differences in emphasis may support more transparent public communication of indication-specific evidence and uncertainty as interest in psilocybin-assisted treatments grows.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.38843","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:30:15Z","timestamp":1792510215000},"page":"e2638843","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Evidence on Psilocybin and Its Representation in Media Reporting"],"prefix":"10.1001","volume":"9","author":[{"given":"Kim","family":"Madden","sequence":"first","affiliation":[{"name":"Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Surgery, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breanne","family":"Flood","sequence":"additional","affiliation":[{"name":"Research Institute of St Joseph\u2019s Hamilton, Hamilton, Ontario, Canada"},{"name":"Centre for Health Research and Innovations on Psychedelics, St Joseph\u2019s Healthcare Hamilton, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Kashir","sequence":"additional","affiliation":[{"name":"Research Institute of St Joseph\u2019s Hamilton, Hamilton, Ontario, Canada"},{"name":"Centre for Health Research and Innovations on Psychedelics, St Joseph\u2019s Healthcare Hamilton, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan","family":"Ahmad","sequence":"additional","affiliation":[{"name":"School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Ali","sequence":"additional","affiliation":[{"name":"School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rotem","family":"Petranker","sequence":"additional","affiliation":[{"name":"Department of Surgery, McMaster University, Hamilton, Ontario, Canada"},{"name":"Centre for Health Research and Innovations on Psychedelics, St Joseph\u2019s Healthcare Hamilton, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"MacKillop","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada"},{"name":"Peter Boris Centre for Addictions Research, McMaster University & St. Joseph\u2019s Healthcare Hamilton, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Adili","sequence":"additional","affiliation":[{"name":"Department of Surgery, McMaster University, Hamilton, Ontario, Canada"},{"name":"Research Institute of St Joseph\u2019s Hamilton, Hamilton, Ontario, Canada"},{"name":"Centre for Health Research and Innovations on Psychedelics, St Joseph\u2019s Healthcare Hamilton, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"zoi261045r1","first-page":"279","article-title":"Lysergsaure-diathylamid, ein phantastikum aus der mutterkorngruppe.","volume":"60","author":"Stoll","year":"1947","journal-title":"Schweiz Arch Neurol Psychiatr"},{"issue":"10","key":"zoi261045r2","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.3390\/molecules26102948","article-title":"The therapeutic potential of psilocybin.","volume":"26","author":"Lowe","year":"2021","journal-title":"Molecules"},{"issue":"11","key":"zoi261045r3","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: past, present, and future.","volume":"42","author":"Carhart-Harris","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"zoi261045r4","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/0006-3223(92)90059-9","article-title":"Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research.","volume":"32","author":"Hermle","year":"1992","journal-title":"Biol Psychiatry"},{"key":"zoi261045r5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/2050324520974484","article-title":"A year of expansion in psychedelic research, industry, and deregulation.","volume":"2020","author":"Aday","year":"2019","journal-title":"Drug Sci Policy Law"},{"issue":"1","key":"zoi261045r6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1080\/03602532.2016.1278228","article-title":"Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance.","volume":"49","author":"Dinis-Oliveira","year":"2017","journal-title":"Drug Metab Rev"},{"issue":"4","key":"zoi261045r7","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin.","volume":"7","author":"Passie","year":"2002","journal-title":"Addict Biol"},{"key":"zoi261045r8","doi-asserted-by":"publisher","DOI":"10.1177\/20451253231198466","article-title":"History repeating: guidelines to address common problems in psychedelic science.","author":"van Elk","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"issue":"10","key":"zoi261045r9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1177\/02698811241269751","article-title":"Psilocybin for clinical indications: a scoping review.","volume":"38","author":"Madden","year":"2024","journal-title":"J Psychopharmacol"},{"issue":"4","key":"zoi261045r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.2853","article-title":"Psilocybin dispensaries and online health claims in Canada.","volume":"8","author":"Matsukubo","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi261045r11","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1215\/03616878-28-5-927","article-title":"Health news and the American public, 1996-2002.","volume":"28","author":"Brodie","year":"2003","journal-title":"J Health Polit Policy Law"},{"key":"zoi261045r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109426","article-title":"Psychedelics: science sabotaged by social media.","volume":"227","author":"Sellers","year":"2023","journal-title":"Neuropharmacology"},{"issue":"71","key":"zoi261045r13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"8","key":"zoi261045r14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.24095\/hpcdp.43.8.04","article-title":"Systematic news media scanning and synthesis: creating a dataset of emergent initiatives and localized responses to public washroom provision in Canada during the COVID-19 pandemic.","volume":"43","author":"Leroux","year":"2023","journal-title":"Health Promot Chronic Dis Prev Can"},{"key":"zoi261045r16","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"1","key":"zoi261045r17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41386-022-01484-1","article-title":"An open label study of COMP360 (synthetic psilocybin) in bipolar type II depression.","volume":"47","author":"Aaronson","year":"2022","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"zoi261045r18","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamapsychiatry.2023.4685","article-title":"Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: a nonrandomized open-label trial.","volume":"81","author":"Aaronson","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"zoi261045r20","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/cncr.35010","article-title":"Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder.","volume":"130","author":"Agrawal","year":"2024","journal-title":"Cancer"},{"issue":"4","key":"zoi261045r21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/ajad.12753","article-title":"Psilocybin-assisted treatment for alcohol use disorder: a clinical perspective.","volume":"27","author":"Amegadzie","year":"2018","journal-title":"Am J Addict"},{"key":"zoi261045r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100538","article-title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study.","volume":"27","author":"Anderson","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"5","key":"zoi261045r23","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2022.565","article-title":"Effects of psilocybin versus escitalopram on rumination and thought suppression in depression.","volume":"8","author":"Barba","year":"2022","journal-title":"BJPsych Open"},{"issue":"1","key":"zoi261045r24","first-page":"1","article-title":"In patients with major depressive disorder, psilocybin administration is associated with reduced amygdala response to negative affective stimuli and normalization of cortical glutamate one week after psilocybin, and improved cognitive flexibility one and four weeks after psilocybin.","volume":"44","author":"Barrett","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"zoi261045r25","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial.","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"zoi261045r26","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1177\/02698811241278873","article-title":"Naturalistic psychedelic therapy: the role of relaxation and subjective drug effects in antidepressant response.","volume":"38","author":"Calder","year":"2024","journal-title":"J Psychopharmacol"},{"issue":"15","key":"zoi261045r27","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression.","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N Engl J Med"},{"key":"zoi261045r28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jad.2018.01.006","article-title":"Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression.","volume":"230","author":"Carrillo","year":"2018","journal-title":"J Affect Disord"},{"issue":"7","key":"zoi261045r29","doi-asserted-by":"publisher","first-page":"690","DOI":"10.35755\/jmedassocthai.2023.07.13864","article-title":"Efficacy of a Thai herbal remedy in patients with mild chronic plaque psoriasis: an observer-blinded randomized, standard treatment-controlled trial.","volume":"106","author":"Chankeaw","year":"2023","journal-title":"J Med Assoc Thai"},{"key":"zoi261045r30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jad.2024.02.089","article-title":"Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity.","volume":"353","author":"Copa","year":"2024","journal-title":"J Affect Disord"},{"issue":"5","key":"zoi261045r31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial.","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"zoi261045r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.110609","article-title":"Acute psychedelic effects and clinical outcomes are associated with therapeutic alliance among participants receiving psilocybin therapy.","volume":"260","author":"Davis","year":"2024","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi261045r33","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41398-021-01706-y","article-title":"Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder.","volume":"11","author":"Doss","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"7","key":"zoi261045r34","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00213-023-06432-5","article-title":"Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing.","volume":"242","author":"Dougherty","year":"2025","journal-title":"Psychopharmacology (Berl)"},{"key":"zoi261045r35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jad.2024.09.133","article-title":"Single-dose psilocybin for US military veterans with severe treatment-resistant depression\u2014a first-in-kind open-label pilot study.","volume":"369","author":"Ellis","year":"2025","journal-title":"J Affect Disord"},{"issue":"5","key":"zoi261045r36","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1177\/02698811241237870","article-title":"Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression.","volume":"38","author":"Erritzoe","year":"2024","journal-title":"J Psychopharmacol"},{"key":"zoi261045r37","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jad.2023.01.108","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression: impact on patient-reported depression severity, anxiety, function, and quality of life.","volume":"327","author":"Goodwin","year":"2023","journal-title":"J Affect Disord"},{"issue":"10","key":"zoi261045r38","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","article-title":"Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.","volume":"48","author":"Goodwin","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"suppl 1","key":"zoi261045r39","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1192\/j.eurpsy.2023.273","article-title":"Improvement in depression symptoms measured by Montgomery-\u00c5sberg Depression Rating Scale and Quick Inventory Of Depressive Symptomatology-self rated items after randomised double-blind COMP360 psilocybin therapy for treatment-resistant depression.","volume":"66","author":"Goodwin","year":"2023","journal-title":"Eur Psychiatry"},{"issue":"1","key":"zoi261045r40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41386-022-01484-1","article-title":"Predicting depression outcomes through the influence of therapeutic alliance and the psychedelic experience using path modelling in a phase IIb randomized controlled trial of COMP360 psilocybin therapy.","volume":"47","author":"Goodwin","year":"2022","journal-title":"Neuropsychopharmacolgy"},{"issue":"1","key":"zoi261045r41","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41386-019-0547-9","article-title":"Psilocybin-assisted treatment of major depressive disorder: results from a randomized trial.","volume":"44","author":"Griffiths","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"zoi261045r42","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial.","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"2","key":"zoi261045r43","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/02698811211073759","article-title":"Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up.","volume":"36","author":"Gukasyan","year":"2022","journal-title":"J Psychopharmacol"},{"key":"zoi261045r44","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1215972","article-title":"Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder.","volume":"14","author":"Heinzerling","year":"2023","journal-title":"Front Psychiatry"},{"issue":"1","key":"zoi261045r45","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-022-01483-2","article-title":"Psilocybin in the treatment of cocaine use disorder.","volume":"47","author":"Hendricks","year":"2022","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"zoi261045r46","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-022-01483-2","article-title":"Psilocybin in the treatment of tobacco use disorder.","volume":"47","author":"Johnson","year":"2022","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"zoi261045r47","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00213-017-4820-5","article-title":"The hidden therapist: evidence for a central role of music in psychedelic therapy.","volume":"235","author":"Kaelen","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"zoi261045r48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0300501","article-title":"The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder.","volume":"19","author":"Levin","year":"2024","journal-title":"PLoS One"},{"issue":"3","key":"zoi261045r49","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jpainsymman.2023.06.006","article-title":"HOPE: a pilot study of psilocybin enhanced group psychotherapy in patients with cancer.","volume":"66","author":"Lewis","year":"2023","journal-title":"J Pain Symptom Manage"},{"issue":"7","key":"zoi261045r50","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1177\/0269881117748902","article-title":"Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression.","volume":"32","author":"Lyons","year":"2018","journal-title":"J Psychopharmacol"},{"issue":"1","key":"zoi261045r51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/head.14656","article-title":"CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity.","volume":"64","author":"Madsen","year":"2024","journal-title":"Headache"},{"issue":"2","key":"zoi261045r52","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/0269881119895520","article-title":"Therapeutic mechanisms of psilocybin: changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression.","volume":"34","author":"Mertens","year":"2020","journal-title":"J Psychopharmacol"},{"issue":"9","key":"zoi261045r53","doi-asserted-by":"publisher","first-page":"S231","DOI":"10.1016\/j.biopsych.2018.02.600","article-title":"T263: psilocybin improves cognitive control and downregulates parietal cortex in treatment-seeking smokers.","volume":"83","author":"McKenna","year":"2018","journal-title":"Biol Psychiatry"},{"key":"zoi261045r54","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.788155","article-title":"Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression.","volume":"12","author":"Murphy","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"zoi261045r55","first-page":"148","article-title":"Psilocybin-assisted therapy in alcohol use disorder: end-of-treatment craving predicts post-treatment drinking behavior.","volume":"47","author":"Pagni","year":"2023","journal-title":"Alcohol Clin Exp Res (Hoboken)"},{"issue":"1","key":"zoi261045r56","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.110063","article-title":"Spontaneous changes in cigarette smoking following psilocybin-assisted treatment for alcohol use disorder.","volume":"260","author":"Pagni","year":"2024","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi261045r57","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1038\/s41598-024-52967-8","article-title":"Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study.","volume":"14","author":"Pagni","year":"2024","journal-title":"Sci Rep"},{"issue":"8","key":"zoi261045r58","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1038\/s41591-023-02455-9","article-title":"Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study.","volume":"29","author":"Peck","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"zoi261045r59","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1177\/02698811241239206","article-title":"Psychedelics and the \u201cinner healer\u201d: myth or mechanism?","volume":"38","author":"Peill","year":"2024","journal-title":"J Psychopharmacol"},{"issue":"9","key":"zoi261045r60","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial.","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"zoi261045r61","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.neuropharm.2017.12.041","article-title":"Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression.","volume":"142","author":"Roseman","year":"2018","journal-title":"Neuropharmacology"},{"issue":"974","key":"zoi261045r62","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression.","volume":"8","author":"Roseman","year":"2018","journal-title":"Front Pharmacol"},{"issue":"3","key":"zoi261045r63","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.medj.2024.01.005","article-title":"Psilocybin-assisted psychotherapy for treatment resistant depression: a randomized clinical trial evaluating repeated doses of psilocybin.","volume":"5","author":"Rosenblat","year":"2024","journal-title":"Med"},{"issue":"2","key":"zoi261045r64","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1021\/acsptsci.1c00020","article-title":"Acute and sustained reductions in loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy for psychiatric and existential distress in life-threatening cancer.","volume":"4","author":"Ross","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"12","key":"zoi261045r65","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"10","key":"zoi261045r66","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/head.14837","article-title":"Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study.","volume":"64","author":"Rucker","year":"2024","journal-title":"Headache"},{"issue":"1","key":"zoi261045r67","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","article-title":"Exploratory controlled study of the migraine-suppressing effects of psilocybin.","volume":"18","author":"Schindler","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"15","key":"zoi261045r68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.122993","article-title":"Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial.","volume":"460","author":"Schindler","year":"2024","journal-title":"J Neurol Sci"},{"key":"zoi261045r69","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jpsychires.2023.03.031","article-title":"Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder.","volume":"161","author":"Schneier","year":"2023","journal-title":"J Psychiatr Res"},{"key":"zoi261045r70","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jad.2022.11.046","article-title":"Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients.","volume":"323","author":"Shnayder","year":"2023","journal-title":"J Affect Disord"},{"issue":"1","key":"zoi261045r71","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/02698811221125354","article-title":"Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression.","volume":"37","author":"Shukuroglou","year":"2023","journal-title":"J Psychopharmacol"},{"issue":"7","key":"zoi261045r72","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1177\/02698811231179800","article-title":"Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: relationship to symptoms.","volume":"37","author":"Skosnik","year":"2023","journal-title":"J Psychopharmacol"},{"issue":"7","key":"zoi261045r73","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1177\/02698811231154852","article-title":"Psilocybin-assisted therapy for major depressive disorder: an exploratory placebo-controlled, fixed-order trial.","volume":"37","author":"Sloshower","year":"2023","journal-title":"J Psychopharmacol"},{"issue":"1","key":"zoi261045r74","doi-asserted-by":"publisher","first-page":"8833","DOI":"10.1038\/s41598-024-58318-x","article-title":"Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial.","volume":"14","author":"Sloshower","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"zoi261045r75","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/02698811221131994","article-title":"Body mass index (BMI) does not predict responses to psilocybin.","volume":"37","author":"Spriggs","year":"2023","journal-title":"J Psychopharmacol"},{"issue":"2","key":"zoi261045r76","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1021\/acsptsci.0c00187","article-title":"Set and setting: a randomized study of different musical genres in supporting psychedelic therapy.","volume":"4","author":"Strickland","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"2","key":"zoi261045r77","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00213-017-4754-y","article-title":"Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression.","volume":"235","author":"Stroud","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"zoi261045r78","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1017\/S0033291723003653","article-title":"Assessing expectancy and suggestibility in a trial of escitalopram v psilocybin for depression.","volume":"54","author":"Szigeti","year":"2024","journal-title":"Psychol Med"},{"issue":"2","key":"zoi261045r79","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae049","article-title":"Brain dynamics predictive of response to psilocybin for treatment-resistant depression.","volume":"6","author":"Vohryzek","year":"2024","journal-title":"Brain Commun"},{"key":"zoi261045r80","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101809","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial.","volume":"56","author":"von Rotz","year":"2022","journal-title":"EClinicalMedicine"},{"key":"zoi261045r82","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jad.2023.04.081","article-title":"Increased low-frequency brain responses to music after psilocybin therapy for depression.","volume":"333","author":"Wall","year":"2023","journal-title":"J Affect Disord"},{"issue":"1","key":"zoi261045r83","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1017\/S0033291723001514","article-title":"Personality change in a trial of psilocybin therapy v escitalopram treatment for depression.","volume":"54","author":"Weiss","year":"2024","journal-title":"Psychol Med"},{"issue":"2","key":"zoi261045r84","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s11469-024-01253-9","article-title":"Unique psychological mechanisms underlying psilocybin therapy versus escitalopram treatment in the treatment of major depressive disorder.","volume":"22","author":"Weiss","year":"2024","journal-title":"Int J Ment Health Addict"},{"key":"zoi261045r85","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jad.2023.04.105","article-title":"How does psilocybin therapy work? an exploration of experiential avoidance as a putative mechanism of change.","volume":"334","author":"Zeifman","year":"2023","journal-title":"J Affect Disord"},{"issue":"9 suppl","key":"zoi261045r86","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2023.02.587","article-title":"Changes in resting state functional connectivity after psilocybin for body dysmorphic disorder.","volume":"93","author":"Zhu","year":"2023","journal-title":"Biol Psychiatry"},{"issue":"7","key":"zoi261045r259","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1177\/02698811231180276","article-title":"Risk of bias in randomized clinical trials on psychedelic medicine: a systematic review.","volume":"37","author":"Hovmand","year":"2023","journal-title":"J Psychopharmacol"},{"key":"zoi261045r260","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2025.1505894","article-title":"Psychedelics assisting therapy, or therapy assisting psychedelics? the importance of psychotherapy in psychedelic-assisted therapy.","volume":"16","author":"Zamaria","year":"2025","journal-title":"Front Psychol"},{"issue":"1","key":"zoi261045r261","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","article-title":"Psychedelic drug legislative reform and legalization in the US.","volume":"80","author":"Siegel","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"zoi261045r263","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1111\/add.16274","article-title":"The implementation and public health impacts of cannabis legalization in Canada: a systematic review.","volume":"118","author":"Hall","year":"2023","journal-title":"Addiction"},{"key":"zoi261045r182","author":"Tobin","year":"2021"},{"key":"zoi261045r184","year":"2022"},{"key":"zoi261045r187","year":"2025"},{"key":"zoi261045r195","year":"2024"},{"key":"zoi261045r196","author":"Rice","year":"2024"},{"key":"zoi261045r198","year":"2024"},{"key":"zoi261045r200","year":"2024"},{"key":"zoi261045r201","year":"2024"},{"key":"zoi261045r228","author":"Nichols","year":"2021"},{"key":"zoi261045r229","year":"2018"},{"key":"zoi261045r235","author":"Junker","year":"2023"},{"key":"zoi261045r241","author":"Kaufmann","year":"2021"},{"key":"zoi261045r250","author":"Havis","year":"2021"},{"key":"zoi261045r15","unstructured":"Covidence. Veritas Health Innovation. Accessed November 7, 2024. https:\/\/www.covidence.org\/"},{"key":"zoi261045r19","unstructured":"Agin-Liebes? G. The Role of Self-Compassion in Psilocybin-Assisted Motivational Enhancement Therapy to Treat Alcohol Dependence: A Randomized Controlled Trial. Dissertation. Palo Alto University; 2019."},{"key":"zoi261045r81","doi-asserted-by":"crossref","unstructured":"Wall? MB, Demetriou? L, Giribaldi? B, . (2023) Reduced brain responsiveness to emotional stimuli with escitalopram but not psilocybin therapy for depression.? medRxiv. Preprint posted online June 3, 2023. doi:10.1101\/2023.05.29.23290667?","DOI":"10.1101\/2023.05.29.23290667"},{"key":"zoi261045r87","unstructured":"Yeung? J. \u201cMagic mushroom\u201d ingredient could be used to treat depression, study says. CNN. December 13, 2019. Accessed November 7, 2024. https:\/\/edition.cnn.com\/2019\/12\/13\/health\/psilocybin-magic-mushrooms-depression-intl-hnk-scli-scn\/index.html"},{"key":"zoi261045r88","unstructured":"Hunt? K. \u201cMagic mushroom\u201d ingredient could work as mental health treatment. CNN. November 7, 2020. Accessed November 7, 2024. https:\/\/edition.cnn.com\/2020\/11\/07\/health\/depression-magic-mushrooms-psilocybin-wellness\/index.html"},{"key":"zoi261045r89","unstructured":"Shorney? S. \u201cI took part in the psilocybin trial and it changed my life.\u201d The Independent. May 23, 2021. Accessed November 7, 2024. https:\/\/www.independent.co.uk\/health-and-wellbeing\/psychedelics-sixties-psilocybin-depression-mental-health-b1831260.html"},{"key":"zoi261045r90","unstructured":"May? NA. \u201cRaft of unanswered questions\u201d remain as Australia\u2019s first psychedelic therapy clinic opens. The Guardian. February 11, 2024. Accessed November 7, 2024. https:\/\/www.theguardian.com\/australia-news\/2024\/feb\/11\/a-raft-of-unanswered-questions-remain-as-australias-first-psychedelic-therapy-clinic-opens"},{"key":"zoi261045r91","unstructured":"McDonald? S. Sara McDonald: I was diagnosed with ALS over 18 months ago and the disease has relentlessly progressed. Vancouver Sun. August 31, 2021. Accessed November 7, 2024. https:\/\/vancouversun.com\/opinion\/sara-mcdonald-i-was-diagnosed-with-als-over-18-months-ago-and-the-disease-has-relentlessly-progressed"},{"key":"zoi261045r92","unstructured":"Active ingredient in magic mushrooms \u201ccould treat anorexia,\u201d experts say. The Herald. July 25, 2023. Accessed November 7, 2024. https:\/\/www.pressreader.com\/uk\/the-herald-1130\/20230725\/281779928617808"},{"key":"zoi261045r93","unstructured":"Altering perception: psychedelic substances are being increasingly tested for therapeutic use for mental health conditions. Financial Express. February 1, 2021. Accessed November 7, 2024. https:\/\/www.financialexpress.com\/opinion\/altering-perception-psychedelic-substances-are-being-increasingly-tested-for-therapeutic-use-for-mental-health-conditions\/2183312\/"},{"key":"zoi261045r94","unstructured":"Duda? J. State to fund clinical trials on \u201cwhole mushroom\u201d psilocybin research. Axios Phoenix. May 19, 2023. Accessed November 7, 2024. https:\/\/www.axios.com\/local\/phoenix\/2023\/05\/19\/arizona-clinical-trials-mushroom-psilocybin-research"},{"key":"zoi261045r95","unstructured":"Acker? L. Applications now open for fund to increase access to Oregon\u2019s legal psilocybin program. The Oregonian. April 30, 2024. Accessed November 7, 2024. https:\/\/www.oregonlive.com\/health\/2024\/04\/applications-now-open-for-fund-to-increase-access-to-oregons-legal-psilocybin-program.html"},{"key":"zoi261045r96","unstructured":"Erickson? K. Advocates lobby for psychedelic drugs to address veteran suicides in Missouri. St. Louis Post-Dispatch. September 1, 2022. Accessed November 7, 2024. https:\/\/www.stltoday.com\/life-entertainment\/local\/wellness\/article_3be054c7-8e5a-59be-a3de-819819c92c94.html"},{"key":"zoi261045r97","unstructured":"Alberta, Canada, leads the way and regulates psychedelic therapy. CE Noticias Financieras. October 6, 2022. Accessed November 7, 2024. https:\/\/www.proquest.com\/docview\/2722675478"},{"key":"zoi261045r98","unstructured":"Allow in Canada to treat depression with psilocybin, a substance in hallucinogenic fungi. CE Noticias Financieras. November 19, 2020. Accessed November 7, 2024. https:\/\/www.proquest.com\/docview\/2462619515"},{"key":"zoi261045r99","unstructured":"Fullerton? O. Psilocybin a potential treatment for eating disorders. YGK News. January 15, 2024. Accessed September 22, 2026. https:\/\/www.pentictonherald.ca\/spare_news\/article_6a16aeda-02ac-5c12-92f2-def6e2b9bb88.html"},{"key":"zoi261045r100","unstructured":"Wertheimer? T. Australia legalises psychedelics for mental health. BBC News. July 1, 2023. Accessed November 7, 2024. https:\/\/www.bbc.com\/news\/world-australia-66072427"},{"key":"zoi261045r101","unstructured":"Australia authorizes medical use of ecstasy and hallucinogenic mushrooms. ContentEngine. July 2, 2023. Accessed November 7, 2024. https:\/\/www.proquest.com\/docview\/2834493218"},{"key":"zoi261045r102","unstructured":"Duxfield? F, Hawley? S. Australia is about to legalise MDMA and psilocybin for medicinal use: so how will it work? ABC News. March 3, 2023. Accessed November 7, 2024. https:\/\/www.abc.net.au\/news\/2023-03-03\/explainer-australia-mdma-and-psilocybin-for-medicinal-use\/102043824"},{"key":"zoi261045r103","unstructured":"Agence France-Presse. Australia to legalise ecstasy, magic mushrooms for medical use from July. The Straits Times. February 3, 2023. Accessed November 7, 2024. https:\/\/www.straitstimes.com\/asia\/australianz\/australia-to-legalise-mdma-and-magic-mushrooms-for-medical-use"},{"key":"zoi261045r104","unstructured":"Bad trips reinforce value of psychedelic industry. CE Noticias Financieras. November 12, 2021. Accessed November 7, 2024. https:\/\/www.proquest.com\/docview\/2597240173"},{"key":"zoi261045r105","unstructured":"Albisu? J. Belgium tests therapy to cure alcoholism with hallucinogenic mushrooms. CE Noticias Financieras. July 19, 2024. Accessed November 7, 2024. https:\/\/www.proquest.com\/docview\/3082894506"},{"key":"zoi261045r106","unstructured":"Brooker? B. Bend your mind around this: the great medicinal psychedelic revival has begun. Crikey. June 7, 2023. Accessed November 7, 2024. https:\/\/www.crikey.com.au\/2023\/06\/07\/medicinal-psychedelic-revival\/"},{"key":"zoi261045r107","unstructured":"Hinchliffe? T. Biotech startup wants to make new short-acting psychedelic drugs more scalable and accessible. The Sociable. April 24, 2020. Accessed November 7, 2024. https:\/\/www.sociable.co\/science\/biotech-short-acting-psychedelic-drugs-scalable-accessible\/"},{"key":"zoi261045r108","unstructured":"Kirkey? S. Calgary man could get assisted death but can\u2019t get access to medical \u201cmagic mushrooms.\u201d National Post. May 29, 2024. Accessed November 7, 2024. https:\/\/nationalpost.com\/health\/calgary-man-could-get-assisted-death-but-not-medical-magic-mushrooms"},{"key":"zoi261045r109","unstructured":"Gorrey? M. Australia missing psychedelic drug \u201crenaissance\u201d for mental health. The Sydney Morning Herald. April 9, 2018. Accessed November 7, 2024. https:\/\/www.smh.com.au\/national\/australia-missing-psychedelic-drug-renaissance-for-mental-health-20180408-p4z8f8.html"},{"key":"zoi261045r110","unstructured":"Bone? E. Can mushrooms treat depression? New York Times. December 3, 2014. Accessed November 7, 2024. https:\/\/www.nytimes.com\/2014\/11\/30\/opinion\/sunday\/can-mushrooms-treat-depression.html"},{"key":"zoi261045r111","unstructured":"Elkins? L. Can new magic mushroom pill treat anorexia? Irish Daily Mail. August 1, 2023. Accessed November 7, 2024. https:\/\/www.irishnews.com\/lifestyle\/health\/2023\/09\/14\/news\/can_new_magic_mushroom_pill_treat_anorexia_-3565513\/"},{"key":"zoi261045r112","unstructured":"Labos? C. Christopher Labos: can psychedelic drugs help with depression? Montreal Gazette. September 27, 2023. Accessed November 7, 2024. https:\/\/montrealgazette.com\/opinion\/columnists\/christopher-labos-can-psychedelic-drugs-help-with-depression"},{"key":"zoi261045r113","unstructured":"Goldstein? L. Can psychedelics alleviate prolonged grief? Austin\u2019s Dell Med School launches clinical trial to find out. Benzinga. October 19, 2022. Accessed November 7, 2024. https:\/\/www.benzinga.com\/markets\/cannabis\/22\/10\/29314729\/can-psychedelics-alleviate-prolonged-grief-austins-dell-med-school-launches-clinical-trial-to-fi"},{"key":"zoi261045r114","unstructured":"Carroll? AE. Can psychedelics be therapy? allow research to find out. New York Times. July 17, 2017. Accessed November 7, 2024. https:\/\/www.nytimes.com\/2017\/07\/17\/upshot\/can-psychedelics-be-therapy-allow-research-to-find-out.html"},{"key":"zoi261045r115","unstructured":"Black Press Media Staff. Canada approves psilocybin for compassionate use in four patients. The Abbotsford News. August 6, 2020. Accessed November 7, 2024. https:\/\/abbynews.com\/2020\/08\/06\/canada-approves-psilocybin-for-compassionate-use-in-four-patients\/"},{"key":"zoi261045r116","unstructured":"TCRN Staff. Canada authorizes the use of psychedelic drugs to treat certain mental illnesses. The Costa Rica News. February 1, 2022. Accessed November 7, 2024. https:\/\/thecostaricanews.com\/canada-authorizes-the-use-of-psychedelic-drugs-to-treat-certain-mental-illnesses\/"},{"key":"zoi261045r117","unstructured":"Canadian patients sue federal government for psilocybin therapy access. InvestorBrandNetwork (IBN). March 30, 2023. Accessed November 7, 2024. https:\/\/rss.investorbrandnetwork.com\/ibn-full\/canadian-patients-sue-federal-government-for-psilocybin-therapy-access\/"},{"key":"zoi261045r118","unstructured":"Martinovic? J. Canadians view psilocybin therapy as \u201creasonable medical choice\u201d for end-of-life distress, new study reveals. Benzinga. February 6, 2024. Accessed November 7, 2024. https:\/\/www.benzinga.com\/markets\/cannabis\/24\/02\/36940810\/canadians-view-psilocybin-therapy-as-reasonable-medical-choice-for-end-of-life-distress-new-stud"},{"key":"zoi261045r119","unstructured":"Goldstein? L. Cannabis & psychedelics as effective adjunct medicine to breast cancer therapy? studies say yes. Benzinga. October 1, 2022. Accessed November 7, 2024. https:\/\/www.benzinga.com\/markets\/cannabis\/22\/09\/29101576\/cannabis-psychedelics-as-effective-adjunct-medicine-to-breast-cancer-therapy"},{"key":"zoi261045r120","unstructured":"Case study documents psychedelics aiding patient\u2019s recovery from long COVID. PsychedelicNewsWire (PNW). June 6, 2024. Accessed November 7, 2024. https:\/\/rss.investorbrandnetwork.com\/pnw\/case-study-documents-psychedelics-aiding-patients-recovery-from-long-covid\/"},{"key":"zoi261045r121","unstructured":"Goldstein? L. Clinical site in Alberta begins study of psychedelic-assisted treatment for alcohol use disorder. Benzinga. February 8, 2023. Accessed November 7, 2024. https:\/\/www.benzinga.com\/markets\/cannabis\/23\/02\/30775843\/clinical-site-in-alberta-begins-study-of-psychedelic-assisted-treatment-for-alcohol-use-disorder"},{"key":"zoi261045r122","unstructured":"Imunoz. Psychedelics and cognition: a new look. Cognitive Neuroscience Society. March 28, 2023. Accessed November 7, 2024. https:\/\/www.cogneurosociety.org\/2023\/psychedelics-and-cognition-a-new-look\/"},{"key":"zoi261045r123","unstructured":"Ponieman? N. Colorado activists push for psilocybin legalization to appear on 2022 ballot. Benzinga. January 27, 2022. Accessed November 7, 2024. https:\/\/www.benzinga.com\/markets\/cannabis\/22\/01\/25241592\/colorado-activists-push-for-psilocybin-legalization-to-appear-on-2022-ballot"},{"key":"zoi261045r124","unstructured":"Colorado says yes to medical use of \u201cmagic mushrooms.\u201d Powers Health. November 15, 2022. Accessed November 7, 2024. https:\/\/www.powershealth.org\/about-us\/newsroom\/health-library\/2022\/11\/14\/colorado-says-yes-to-medical-use-of-magic-mushrooms"},{"key":"zoi261045r125","unstructured":"Brodie? J. Coming up from underground. The Sunday Times. April 11, 2021. Accessed November 7, 2024. https:\/\/www.sundaytimes.timeslive.co.za\/sunday-times\/lifestyle\/health-and-sex\/2021-04-11-alter-your-mind-about-shrooms-could-they-be-magical-for-mental-health\/"},{"key":"zoi261045r126","unstructured":"Controversy grows over necessity of hallucinogenic experiences during psychedelic therapy. PsychedelicNewsWire. March 29, 2023. Accessed November 7, 2024. https:\/\/rss.investorbrandnetwork.com\/pnw\/controversy-grows-over-necessity-of-hallucinogenic-experiences-during-psychedelic-therapy\/"},{"key":"zoi261045r127","unstructured":"Core One Labs applauds Health Canada\u2019s amendments to Special Access Program, allowing physicians to request patient access to psychedelic treatments. GlobeNewswire. January 6, 2022. Accessed November 7, 2024. https:\/\/www.globenewswire.com\/news-release\/2022\/01\/06\/2362085\/0\/en\/Core-One-Labs-Applauds-Health-Canada-s-Amendments-to-Special-Access-Program-Allowing-Physicians-to-Request-Patient-Access-to-Psychedelic-Treatments.html"},{"key":"zoi261045r128","unstructured":"Could magic mushrooms be used to treat resistant depression? RTE. August 31, 2022. Accessed November 7, 2024. https:\/\/www.rte.ie\/lifestyle\/living\/2022\/0831\/1319780-could-magic-mushrooms-be-used-to-treat-resistant-depression\/"},{"key":"zoi261045r129","unstructured":"Allen? V. Could magic mushrooms in care homes help curb fear of death? psychedelic drugs could \u201crevolutionise\u201d end-of-life treatment, expert says. Daily Mail. June 14, 2022. Accessed November 7, 2024. https:\/\/www.dailymail.co.uk\/sciencetech\/article-10913333\/Could-magic-mushrooms-help-curb-fear-death-care-homes.html"},{"key":"zoi261045r130","unstructured":"Spinelli? J. Could psilocybin be a game-changer for millions battling depression? new study says yes. Benzinga. October 8, 2024. Accessed November 7, 2024. https:\/\/www.benzinga.com\/markets\/cannabis\/24\/10\/41216395\/could-psilocybin-be-a-game-changer-for-millions-battling-depression-new-study-says-yes"},{"key":"zoi261045r131","unstructured":"Could psychedelic experiences help combat anxiety and depression? CE Noticias Financieras. February 25, 2023. Accessed November 7, 2024. https:\/\/www.proquest.com\/docview\/2780173852"},{"key":"zoi261045r132","unstructured":"Cuncliffe? R. David Nutt: \u201cit\u2019s the biggest breakthrough in mental health for 50 years.\u201d The New Statesman. July 20, 2023. Accessed November 7, 2024. https:\/\/www.newstatesman.com\/encounter\/2023\/07\/david-nutt-interview-depression-treatment-mental-health"},{"key":"zoi261045r133","unstructured":"Morin? R. Do psychedelic drug laws violate human rights? The Atlantic. March 4, 2016. Accessed November 7, 2024. https:\/\/www.theatlantic.com\/health\/archive\/2016\/03\/psychedelic-drugs\/471603\/"},{"key":"zoi261045r134","unstructured":"Grochowski? S. Docs regain access to psychedelics: psilocybin, MDMA considered for patients with treatment-resistant mental-health illnesses. The Province. January 18, 2022. Accessed November 7, 2024. https:\/\/www.pressreader.com\/canada\/the-province\/20220118\/281526524424413?srsltid=AU7gw4XMFtwgr0RufwioUxjSuw3LHiyzmye56zbmb8mGtsoKRBbZjtJd"},{"key":"zoi261045r135","unstructured":"Lee? M. Doctors urge access to psychedelic therapies in New Mexico. AP News. July 13, 2022. Accessed November 7, 2024. https:\/\/apnews.com\/article\/health-new-mexico-santa-fe-alcoholism-0f519c0b39bac254bbd705542d7bfabc"},{"key":"zoi261045r136","unstructured":"Experts call for psychedelics to be investigated as cancer distress treatments. PsychedelicNewsWire. August 22, 2023. Accessed November 7, 2024. https:\/\/rss.investorbrandnetwork.com\/ibn-full\/experts-call-for-psychedelics-to-be-investigated-as-cancer-distress-treatments\/"},{"key":"zoi261045r137","unstructured":"Torreilles S. FDA permits psilocybin to be tested for refractory depression. Medscape Medical News. October 30, 2018. Accessed September 22, 2026. https:\/\/www.medscape.com\/viewarticle\/904159"},{"key":"zoi261045r138","unstructured":"Psychedelic products represent a new frontier for mental health. Mental Health Weekly Digest. June 15, 2020. Accessed November 7, 2024. https:\/\/www.medindia.net\/health-press-release\/Psychedelic-Products-Represent-a-New-Frontier-for-Mental-Health-471528-1.htm"},{"key":"zoi261045r139","unstructured":"First Alberta clinical site for study of psychedelic-assisted treatment for alcohol use disorder approved. Business Wire. February 2, 2023. Accessed November 7, 2024. https:\/\/www.businesswire.com\/news\/home\/20230202005023\/en\/First-Alberta-Clinical-Site-for-Study-of-Psychedelic-Assisted-Treatment-for-Alcohol-Use-Disorder-Approved"},{"key":"zoi261045r140","unstructured":"Ann? V. First patient in Quebec gets approval from Health Canada for magic mushroom therapy. Global News. May 16, 2022. Accessed November 7, 2024. https:\/\/globalnews.ca\/news\/8838328\/quebec-magic-mushroom-therapy-health-canada\/"},{"key":"zoi261045r141","unstructured":"Kaufmann? B. Airdrie cancer patient first Albertan to undergo legal magic mushroom therapy. The Seed Investor. January 10, 2021. Accessed September 22, 2026. https:\/\/theseedinvestor.com\/cannabis-news\/airdrie-cancer-patient-first-albertan-to-undergo-legal-magic-mushroom-therapy"},{"key":"zoi261045r142","unstructured":"Harper? M. Florida could become latest state to study \u201cmagic mushrooms\u201d as mental health treatment. USA Today. October 7, 2021. Accessed September 22, 2026. https:\/\/www.usatoday.com\/story\/news\/nation\/2021\/10\/07\/florida-could-study-psychedelic-therapies-mental-health-treatment\/6040662001\/"},{"key":"zoi261045r143","unstructured":"May? K. Funding needed to pursue \u201cgreat interest\u201d in psilocybin: researcher. The Free Press. May 25, 2023. Accessed November 7, 2024. https:\/\/winnipegfreepress.com\/breakingnews\/2023\/05\/24\/funding-needed-to-pursue-great-interest-in-psilocybin-researcher"},{"key":"zoi261045r144","unstructured":"Goldstein? L. Global psychedelics: Australia\u2019s prescription guidelines, New Zealand\u2019s meth addiction treatment. Benzinga. November 25, 2023. Accessed November 7, 2024. https:\/\/www.benzinga.com\/markets\/cannabis\/23\/11\/35944632\/global-psychedelics-australias-prescription-guidelines-new-zealands-meth-addiction-treatment"},{"key":"zoi261045r145","unstructured":"Golden teacher mushroom as medicine. Antigua News Room. October 25, 2021. Accessed November 7, 2024. https:\/\/antiguanewsroom.com\/golden-teacher-mushroom-as-medicine\/"},{"key":"zoi261045r146","unstructured":"Canadian Institutes of Health Research. Government of Canada invests nearly $3 million to study the potential benefits of psilocybin-assisted psychotherapy. Contify Life Science News. June 29, 2023. Accessed November 7, 2024. https:\/\/www.canada.ca\/en\/institutes-health-research\/news\/2023\/06\/government-of-canada-invests-nearly-3-million-to-study-the-potential-benefits-of-psilocybin-assisted-psychotherapy.html"},{"key":"zoi261045r147","unstructured":"Bird? I. Tasmanian GP says MDMA and psilocybin can solve mental health crisis. The Advocate. March 26, 2021. Accessed September 22, 2026. https:\/\/www.theadvocate.com.au\/story\/7183597\/tasmanian-gp-says-mdma-and-psilocybin-can-solve-mental-health-crisis\/"},{"key":"zoi261045r148","unstructured":"Group psychotherapy coupled with psilocybin shows promise for cancer patients. InvestorBrandNetwork (IBN). July 13, 2023. Accessed November 7, 2024. https:\/\/rss.investorbrandnetwork.com\/ibn-full\/group-psychotherapy-coupled-with-psilocybin-shows-promise-for-cancer-patients\/"},{"key":"zoi261045r149","unstructured":"Phillip? A. Hallucinogen in \u201cmagic mushrooms\u201d might have helped smokers quit. The Washington Post. September 12, 2014. Accessed November 7, 2024. https:\/\/www.washingtonpost.com\/news\/to-your-health\/wp\/2014\/09\/12\/hallucinogen-in-magic-mushrooms-might-have-helped-smokers-quit\/"},{"key":"zoi261045r150","unstructured":"Hallucinogenic mushrooms are effective against depression and anxiety, study concludes. ContentEngine. July 28, 2024. Accessed November 7, 2024. https:\/\/www.proquest.com\/docview\/3085816396"},{"key":"zoi261045r151","unstructured":"Baig F. Health-care professionals fight decision to reject access to psilocybin for training. Abbotsford News. March 29, 2023. Accessed September 22, 2026. https:\/\/www.torontotoday.ca\/national-news\/health-care-professionals-fight-decision-to-reject-access-to-psilocybin-for-training-6772098"},{"key":"zoi261045r152","unstructured":"Chambers? M. Micro-dosing: high hopes and mixed expectations. Edmonton Journal. January 26, 2023. Accessed November 7, 2024. https:\/\/www.pressreader.com\/canada\/edmonton-journal\/20230125\/282033331325597"},{"key":"zoi261045r153","unstructured":"Gallivan? J. How advocates are trying to reduce the cost of magic mushroom therapy. Axios. June 26, 2024. Accessed November 7, 2024. https:\/\/www.msn.com\/en-us\/health\/other\/how-advocates-are-trying-to-reduce-the-cost-of-magic-mushroom-therapy\/ar-BB1oVTWK"},{"key":"zoi261045r154","unstructured":"How psychedelics are returning to the world of medicine. Deutsche Welle. October 3, 2021. Accessed November 7, 2024. https:\/\/indianexpress.com\/article\/explained\/explained-how-psychedelics-returning-world-medicine\/"},{"key":"zoi261045r155","unstructured":"How psychedelics could benefit mental health of women. InvestorBrandNetwork (IBN). March 14, 2023. Accessed November 7, 2024. https:\/\/rss.investorbrandnetwork.com\/ibn-full\/how-psychedelics-could-benefit-mental-health-of-women\/?"},{"key":"zoi261045r156","unstructured":"Seisdedos? I. How the United States embraced psychedelics. El Pais. February 13, 2024. Accessed November 7, 2024. https:\/\/english.elpais.com\/health\/2024-02-13\/how-the-united-states-embraced-psychedelics.html"},{"key":"zoi261045r157","unstructured":"Harkins? P. How to navigate Utah\u2019s \u201cwild west\u201d of psychedelic-assisted therapy options. The Salt Lake Tribune. May 4, 2024. Accessed November 7, 2024. https:\/\/www.sltrib.com\/news\/2024\/05\/04\/how-navigate-utahs-wild-west\/"},{"key":"zoi261045r158","unstructured":"Holson? LM. Imagine...magic mushrooms are getting closer to medical use. The Hamilton Spectator. November 3, 2018. Accessed November 7, 2024. https:\/\/www.thespec.com\/life\/health-wellness\/imagine-magic-mushrooms-are-getting-closer-to-medical-use\/article_cd734f21-53d9-546f-a6fb-6459a379f950.html"},{"key":"zoi261045r159","unstructured":"Increased use of psilocybin for anxiety. CE Noticias Financieras. August 12, 2024. Accessed November 7, 2024. https:\/\/www.proquest.com\/docview\/3092568921"},{"key":"zoi261045r160","unstructured":"Essex? R. Indiana lawmakers considering bill legalizing magic mushrooms for research. WDRB. January 27, 2024. Accessed November 7, 2024. https:\/\/www.indystar.com\/story\/news\/politics\/2024\/01\/17\/magic-mushrooms-for-depression-indiana-considers-bill-to-fund-research\/72254720007\/"},{"key":"zoi261045r161","unstructured":"McKay? B. Inside Alberta\u2019s promising psychedelic-assisted therapy industry. The Canadian Press. April 27, 2024. Accessed November 7, 2024. https:\/\/www.stalbertgazette.com\/local-news\/inside-albertas-promising-psychedelic-assisted-therapy-industry-8541878"},{"key":"zoi261045r162","unstructured":"Brown? EN. Inside the growing wellness trend of psilocybin mushroom microdosing. The Hollywood Reporter. January 23, 2022. Accessed November 7, 2024. https:\/\/www.hollywoodreporter.com\/lifestyle\/lifestyle-news\/pyschedelic-mushrooms-microdosing-medical-treatment-1235076616\/"},{"key":"zoi261045r163","unstructured":"It\u2019s time to unshackle psilocybin for research. The Capital Times & Wisconsin State Journal. June 2, 2024. Accessed November 7, 2024. https:\/\/global-factiva-com.libaccess.lib.mcmaster.ca\/hp\/printsavews.aspx?ppstype=Article&pp=Save&hc=Publication"},{"key":"zoi261045r164","unstructured":"Scharper? J. Preparing for a new era of psychedelic treatment. Johns Hopkins Magazine. September 9, 2022. Accessed November 7, 2024. https:\/\/hub.jhu.edu\/magazine\/2022\/fall\/new-era-of-psychedelic-treatment\/"},{"key":"zoi261045r165","unstructured":"Pearce? K. With Oregon\u2019s ballot measure, a path opens for legal medical mushrooms. Johns Hopkins Hub. December 2, 2020. Accessed November 7, 2024. https:\/\/hub.jhu.edu\/2020\/12\/02\/mushrooms-legalization-johnson\/"},{"key":"zoi261045r166","unstructured":"Kentucky commission receives expert testimonies on psychedelics benefits as opioid treatments. InvestorBrandNetwork (IBN). July 27, 2023. Accessed November 7, 2024. https:\/\/rss.investorbrandnetwork.com\/pnw-full\/kentucky-commission-receives-expert-testimonies-on-psychedelics-benefits-as-opioid-treatments\/"},{"key":"zoi261045r167","unstructured":"Kjolseth? F. Letter: a new hope for mental health in Utah: embracing medical psychedelics. The Salt Lake Tribune. July 5, 2023. Accessed November 7, 2024. https:\/\/www.sltrib.com\/opinion\/letters\/2023\/07\/05\/letter-new-hope-mental-health-utah\/"},{"key":"zoi261045r168","unstructured":"Cook? K. Letter: therapeutic use of psychedelic medicine is very promising\u2014research must not be stymied. The Salt Lake Tribune. September 18, 2024. Accessed November 7, 2024. https:\/\/www.sltrib.com\/opinion\/letters\/2024\/09\/18\/letter-therapeutic-use-psychedelic\/"},{"key":"zoi261045r169","unstructured":"Goldstein? L. Link between cancer and psilocybin: research on this palliative promise. Benzinga. May 23, 2023. Accessed November 7, 2024. https:\/\/www.benzinga.com\/markets\/cannabis\/23\/05\/32495150\/link-between-cancer-and-psilocybin-research-on-this-palliative-promise"},{"key":"zoi261045r170","unstructured":"Wang? Z. London start-up starts testing psychedelics to treat mental conditions. The Standard. October 10, 2022. Accessed November 7, 2024. https:\/\/www.standard.co.uk\/news\/tech\/psychedelics-mental-conditions-treatment-london-b1031580.html"},{"key":"zoi261045r171","unstructured":"Wilson? J. Long, strange trip kicked off the journey to recovery. The Sydney Morning Herald. March 3, 2020. Accessed November 7, 2024. https:\/\/global-factiva-com.libaccess.lib.mcmaster.ca\/hp\/printsavews.aspx?ppstype=Article&pp=Print&hc=Publication"},{"key":"zoi261045r172","unstructured":"Madrigal Mental Care develops treatment for post-traumatic stress disorder based on psychedelic drugs. PR Newswire. May 9, 2022. Accessed November 7, 2024. https:\/\/www.prnewswire.com\/news-releases\/madrigal-mental-care-develops-treatment-for-post-traumatic-stress-disorder-based-on-psychedelic-drugs-301542361.html"},{"key":"zoi261045r173","unstructured":"Gregory? A. Magic mushroom compound psilocybin found safe for consumption in largest ever controlled study. The Independent. December 19, 2019. Accessed November 7, 2024. https:\/\/www.independent.co.uk\/news\/health\/magic-mushroom-depression-psilocybin-trials-kcl-mental-health-addiction-a9251451.html"},{"key":"zoi261045r174","unstructured":"Sullivan? N. Magic mushrooms and end of life care: Cape Breton psychologist hosting talk about psilocybin benefits on terminally ill people. PNI Atlantic News. February 22, 2024. Accessed November 7, 2024. https:\/\/www.saltwire.com\/atlantic-canada\/news\/magic-mushrooms-and-end-of-life-care-cape-breton-psychologist-hosting-talk-about-psilocybin-benefits-on-terminally-ill-people-100940767\/"},{"key":"zoi261045r175","unstructured":"Nelson? J. Magic mushrooms are a promising treatment for depression, new study finds. Emerge. September 25, 2024. Accessed August 6, 2026. https:\/\/decrypt.co\/251025\/magic-mushrooms-promising-treatment-depression"},{"key":"zoi261045r176","unstructured":"Gallagher? J. Magic mushrooms can \u201creset\u201d depressed brain. BBC News. October 14, 2017. Accessed November 7, 2024. https:\/\/www.bbc.com\/news\/health-41608984"},{"key":"zoi261045r177","unstructured":"Kelland? K. Magic mushrooms could be last resort treatment for severe depression, study finds. The Sydney Morning Herald. May 19, 2016. Accessed November 7, 2024. https:\/\/www.smh.com.au\/healthcare\/magic-mushrooms-could-be-last-resort-treatment-for-severe-depression-study-finds-20160517-goxgnx.html"},{"key":"zoi261045r178","unstructured":"Cannabis.net. Magic mushrooms: a potential cure for color blindness? new case study has interesting results. Benzinga. June 29, 2023. Accessed November 7, 2024. https:\/\/www.benzinga.com\/markets\/cannabis\/23\/06\/33011181\/magic-mushrooms-a-potential-cure-for-color-blindness-new-case-study-has-interesting-results"},{"key":"zoi261045r179","unstructured":"Brubaker? H. Mushrooms\u2019 moment? bill aims to put Pa. ahead in psychedelic research. The Philadelphia Inquirer. November 15, 2021. Accessed November 7, 2024. https:\/\/www.inquirer.com\/business\/health\/psilocybin-research-pennsylvania-veterans-ptsd-depression-suicide-20211115.html"},{"key":"zoi261045r180","doi-asserted-by":"crossref","unstructured":"White? CM. Psychedelics may better treat depression and anxiety symptoms than prescription antidepressants for patients with advanced cancer. The Conversation. April 17, 2023. Accessed November 7, 2024. https:\/\/theconversation.com\/psychedelics-may-better-treat-depression-and-anxiety-symptoms-than-prescription-antidepressants-for-patients-with-advanced-cancer-201937","DOI":"10.64628\/AAI.qnq3qdwtq"},{"key":"zoi261045r181","unstructured":"Farid? F. Psychedelics could help with mental health. AAP Bulletins. May 18, 2022. Accessed September 22, 2026. https:\/\/www.redlandcitybulletin.com.au\/story\/7742659\/psychedelics-could-help-with-mental-health\/"},{"key":"zoi261045r183","unstructured":"Oregon in final challenge to authorize psilocybin from cogumelos. ContentEngine. September 22, 2022. Accessed November 7, 2024. https:\/\/www.proquest.com\/docview\/2717303997"},{"key":"zoi261045r185","unstructured":"Johnson? CK. Believers say microdosing psychedelics helps them: scientists are trying to measure the claims. Associated Press Newswire. April 17, 2025. Accessed November 7, 2024. https:\/\/apnews.com\/article\/microdosing-lsd-mushrooms-psychedelic-psilocybin-390c99ba54ef9d75727f39e2ec78fb34"},{"key":"zoi261045r186","unstructured":"Bartlett? SL. A trip into the fine print of ballot question 4: MA\u2019s proposal to legalize certain natural psychedelic substances. Mondaq. April 2, 2025. Accessed November 7, 2024. https:\/\/www.mondaq.com\/unitedstates\/cannabis-hemp\/1604096\/a-trip-into-the-fine-print-of-ballot-question-4-mas-proposal-to-legalize-certain-natural-psychedelic-substances"},{"key":"zoi261045r188","unstructured":"Carlino? M. Nevada Assembly Bill 378 could help patients access psychedelic therapies. Reason Foundation. March 26, 2025. Accessed November 7, 2024. https:\/\/reason.org\/testimony\/nevada-assembly-bill-378-could-help-patients-access-psychedelic-therapies\/"},{"key":"zoi261045r189","unstructured":"Study finds that the mental wellbeing effects of psilocybin vary by race. Investor Brand Network. March 17, 2025. Accessed November 7, 2024. https:\/\/rss.investorbrandnetwork.com\/ibn-full\/study-finds-that-the-mental-wellbeing-effects-of-psilocybin-vary-by-race\/"},{"key":"zoi261045r190","unstructured":"School of Health Professions. Psychedelic therapy: jury\u2019s still out. Texas Tech University Health Sciences Center Daily Dose. March 12, 2025. Accessed November 7, 2024. https:\/\/www.ttuhsc.edu\/stories\/psychedelic-therapy-jurys-still-out"},{"key":"zoi261045r191","unstructured":"Adelstone? J. Ninth Circuit issues disappointing ruling on terminally ill patients and psilocybin. Mondaq. February 19, 2025. Accessed November 7, 2024. https:\/\/www.mondaq.com\/unitedstates\/healthcare\/1586244\/ninth-circuit-issues-disappointing-ruling-on-terminally-ill-patients-and-psilocybin"},{"key":"zoi261045r192","unstructured":"Clouser? T. From \u201cjust say no\u201d to \u201cmaybe so\u201d? Olympia reconsiders legalizing psychedelics. The Center Square. January 30, 2025. Accessed November 7, 2024. https:\/\/www.thecentersquare.com\/national\/article_1e0683ca-df53-11ef-a4a4-77a2f4145668.html"},{"key":"zoi261045r193","unstructured":"Gelperin? R. The fountainhead of the psychedelic renaissance. The Libertarian Institute. January 16, 2025. Accessed November 7, 2024. https:\/\/libertarianinstitute.org\/articles\/the-fountainhead-of-the-psychedelic-renaissance\/"},{"key":"zoi261045r194","unstructured":"Vrije Universiteit Amsterdam. Brain research with psychedelic substances. Vrije Universiteit Amsterdam. January 13, 2025. Accessed November 7, 2024. https:\/\/vu.nl\/en\/news\/2025\/brain-research-with-psychedelic-substances"},{"key":"zoi261045r197","unstructured":"VA funds first study on psychedelic-assisted therapy for veterans. US Dept of Veterans Affairs. December 3, 2024. Accessed November 7, 2024. https:\/\/news.va.gov\/press-room\/va-funds-first-study-on-psychedelic-assisted-therapy-for-veterans\/"},{"key":"zoi261045r199","unstructured":"Psychedelics task force in Vermont calls for education on harm reduction. Psychedelic News Network. November 20, 2024. Accessed September 22, 2026. https:\/\/www.psychedelicnewswire.com\/psychedelics-task-force-in-vermont-calls-for-education-on-harm-reduction\/"},{"key":"zoi261045r202","unstructured":"Study shows psychedelic therapies for some mental illnesses to be legalized. India Education Diary. June 4, 2023. Accessed November 7, 2024. https:\/\/indiaeducationdiary.in\/study-shows-psychedelic-therapies-for-some-mental-illnesses-to-be-legalized\/"},{"key":"zoi261045r203","unstructured":"Study reveals psilocybin-assisted therapy lessens depressive symptoms in adults with cancer and depression. Asian News International. December 23, 2023. Accessed November 7, 2024. https:\/\/www.aninews.in\/news\/health\/study-reveals-psilocybin-assisted-therapy-lessens-depressive-symptoms-in-adults-with-cancer-depression20231223152248\/"},{"key":"zoi261045r204","unstructured":"Kaufmann? B. Mushrooms\u2019 potential magic in quelling alcohol abuse the focus of U of C researchers. Calgary Herald. March 21, 2024. Accessed November 7, 2024. https:\/\/calgaryherald.com\/news\/local-news\/mushrooms-potential-magic-in-halting-alcohol-abuse"},{"key":"zoi261045r205","unstructured":"Duffy? A. Ottawa\u2019s strange state of psilocybin. Ottawa Citizen. September 16, 2023. Accessed November 7, 2024. https:\/\/ottawacitizen.com\/feature\/ottawas-strange-state-of-psilocybin"},{"key":"zoi261045r206","unstructured":"Kriszenfeld? D, Brown? E. So mushroom to grow: psilocybin and Canada\u2019s regulatory landscape. Mondaq. October 19, 2021. Accessed November 7, 2024. https:\/\/www.mondaq.com\/canada\/healthcare\/1122414\/so-mushroom-to-grow-psilocybin-and-canadas-regulatory-landscape"},{"key":"zoi261045r207","unstructured":"Mushrooms to quit alcohol. ContentEngine. October 2, 2022. Accessed November 7, 2024. https:\/\/www.proquest.com\/docview\/2720820603"},{"key":"zoi261045r208","unstructured":"Cannabis.net. Should I tell my doctor if I take psychedelic shrooms? most people don\u2019t, but... Benzinga. September 25, 2023. Accessed November 7, 2024. https:\/\/www.benzinga.com\/markets\/cannabis\/23\/09\/34702745\/should-i-tell-my-doctor-if-i-take-psychedelic-shrooms-most-people-dont-but"},{"key":"zoi261045r209","unstructured":"Martinovic? J. Seattle physician launches push to reschedule psilocybin for medical use. Benzinga. February 5, 2022. Accessed November 7, 2024. https:\/\/www.benzinga.com\/markets\/cannabis\/22\/02\/25426637\/seattle-physician-launches-push-to-reschedule-psilocybin-for-medical-use"},{"key":"zoi261045r210","unstructured":"Carey? B. Scientists bet on psychedelic drugs to treat mental health problems. New York Times. September 8, 2019. Accessed November 7, 2024. https:\/\/www.proquest.com\/docview\/2287334830"},{"key":"zoi261045r211","unstructured":"Atter? H. Sask. man first in Canada to legally use magic mushrooms in therapy. CBC. August 24, 2020. Accessed November 7, 2024. https:\/\/www.cbc.ca\/news\/canada\/saskatchewan\/thomas-hartle-magic-mushroom-psilocybin-therapy-1.5700371"},{"key":"zoi261045r212","unstructured":"Revive Therapeutics Ltd. Revive Therapeutics files for FDA orphan drug designation for psilocybin in traumatic brain injury. GlobeNewswire. April 27, 2021. Accessed November 7, 2024. https:\/\/www.globenewswire.com\/news-release\/2021\/04\/27\/2217794\/0\/en\/Revive-Therapeutics-Files-for-FDA-Orphan-Drug-Designation-for-Psilocybin-in-Traumatic-Brain-Injury.html"},{"key":"zoi261045r213","unstructured":"Reducing trip duration crucial to mass adoption of psychedelic therapies. PsychedelicNewsWire. March 21, 2023. Accessed November 7, 2024. https:\/\/www.psychedelicnewswire.com\/reducing-trip-duration-crucial-to-mass-adoption-of-psychedelic-therapies\/"},{"key":"zoi261045r214","unstructured":"Filby? M. Can the psychedelic in magic mushrooms treat depression? Ohio State professor weighs in. The Ohio State University College of Social Work. February 18, 2024. Accessed November 7, 2024. https:\/\/www.dispatch.com\/story\/news\/healthcare\/2024\/02\/14\/ohio-state-professor-psychedelic-therapy-likely-to-get-fda-approval\/72574116007\/"},{"key":"zoi261045r215","unstructured":"Napier-Raman? K. Psychiatrists split over the use of \u2019shrooms and MDMA to treat mental illness. Crikey. February 12, 2021. Accessed November 7, 2024. https:\/\/www.crikey.com.au\/2021\/02\/12\/psychiatrists-shrooms-mdma-mental-illness\/"},{"key":"zoi261045r216","unstructured":"Khan? I. Psychedelics: expanding the therapeutic toolkit. Prospect. December 8, 2022. Accessed November 7, 2024. https:\/\/www.prospectmagazine.co.uk\/politics\/60295\/psychedelics-expanding-the-therapeutic-toolkit"},{"key":"zoi261045r217","unstructured":"Kalensky? M. Psychedelic-assisted therapy: applications in mental health. Clinical Advisor. April 15, 2022. Accessed November 7, 2024. https:\/\/www.clinicaladvisor.com\/features\/psychedelics-applications-in-mental-health\/"},{"key":"zoi261045r218","unstructured":"Psychedelics may help manage long COVID-19 symptoms. PsychedelicNewsWire. April 21, 2023. Accessed November 7, 2024. https:\/\/www.psychedelicnewswire.com\/psychedelics-may-help-manage-long-covid-19-symptoms\/"},{"key":"zoi261045r219","unstructured":"Wilson? C. Psychedelics hype may lead people to self-medicate. New Scientist. October 11, 2023. Accessed November 7, 2024. https:\/\/go.gale.com\/ps\/i.do?p=ITOF&id=GALE%7CA769356422&v=2.1&it=r"},{"key":"zoi261045r220","unstructured":"Paul? A. Psychedelics can make your brain grow more cells but they are no magic solution. DailyO. March 2, 2023. Accessed November 7, 2024. https:\/\/www.dailyo.in\/news\/psychedelics-can-make-your-brain-grow-more-cells-but-they-are-no-magic-solution-39081"},{"key":"zoi261045r221","unstructured":"Carhart-Harris? R. Psychedelics are transforming the way we understand depression and its treatment. The Guardian. April 20, 2021. Accessed November 7, 2024. https:\/\/www.theguardian.com\/commentisfree\/2021\/apr\/20\/psychedelics-depression-treatment-psychiatry-psilocybin"},{"key":"zoi261045r222","unstructured":"Ferenstein? G. Psychedelics and mental health care\u2014what policymakers need to know. Niskanen Center. May 22, 2020. Accessed November 7, 2024. https:\/\/www.niskanencenter.org\/psychedelics-and-mental-health-care-what-policymakers-need-to-know\/"},{"key":"zoi261045r223","unstructured":"Psychedelics alleviate depression by disrupting connectivity between brain regions. ContentEngine. July 17, 2024. Accessed November 7, 2024. https:\/\/www.proquest.com\/docview\/3082498459"},{"key":"zoi261045r224","unstructured":"Psychedelic drugs without hallucinations to treat depression. ContentEngine. January 27, 2022. Accessed November 7, 2024. https:\/\/www.proquest.com\/docview\/2623563336"},{"key":"zoi261045r225","unstructured":"Davey? M. Psychedelic treatment in mental health lacks evidence, Australian experts say. The Guardian. September 13, 2023. Accessed November 7, 2024. https:\/\/www.theguardian.com\/australia-news\/2023\/sep\/13\/psychedelic-treatment-in-mental-health-lacks-evidence-australian-experts-say"},{"key":"zoi261045r226","unstructured":"Magann? K. Psychedelic therapies will soon be legal in Australia. The Examiner. May 15, 2023. Accessed November 7, 2024. https:\/\/www.examiner.com.au\/story\/8196344\/psychedelic-therapies-will-soon-be-legal-in-australia\/"},{"key":"zoi261045r227","unstructured":"\u201cPsychedelic renaissance\u201d: science revives psychoactive drugs\u2019 therapeutic potential. ContentEngine. July 8, 2023. Accessed November 7, 2024. https:\/\/www.proquest.com\/docview\/2834944242"},{"key":"zoi261045r230","unstructured":"Aguila? R. FDA approve \u201cmagic mushroom\u201d treatment. U-Wire. September 12, 2018. Accessed September 22, 2026. https:\/\/www.talonmarks.com\/opinion\/2018\/09\/12\/fda-approve-magic-mushroom-treatment\/"},{"key":"zoi261045r231","unstructured":"Psychedelic drugs open new paradigm in the treatment of mental disorders. ContentEngine. October 8, 2022. Accessed November 7, 2024. https:\/\/www.proquest.com\/docview\/2723058996"},{"key":"zoi261045r232","unstructured":"Psychedelic drugs may be ready for medical comeback. The Hamilton Spectator. September 8, 2015. Accessed November 7, 2024. https:\/\/www.latimes.com\/science\/sciencenow\/la-sci-sn-psychedelic-drugs-medical-comeback-20150908-story.html"},{"key":"zoi261045r233","unstructured":"Psychedelic drugs could potentially treat impending post-lockdown mental health epidemic. PR Newswire. June 2, 2020. Accessed November 7, 2024. https:\/\/www.prnewswire.co.uk\/news-releases\/psychedelic-drugs-could-potentially-treat-impending-post-lockdown-mental-health-epidemic-889077235.html"},{"key":"zoi261045r234","unstructured":"TCRN Staff. Psilocybin: a journey beyond the fear of death. The Costa Rica News. January 16, 2022. Accessed November 7, 2024. https:\/\/thecostaricanews.com\/psilocybin-a-journey-beyond-the-fear-of-death\/"},{"key":"zoi261045r236","unstructured":"Psilocybin shown to be useful in treating distress in women with advanced gynecologic cancers. ContentEngine. July 19, 2023. Accessed November 7, 2024. https:\/\/www.proquest.com\/docview\/2840270158"},{"key":"zoi261045r237","unstructured":"Bola\u00f1o? CS. Psilocybin: from magic mushrooms to the doctor\u2019s office? Mexico News Daily. October 24, 2023. Accessed November 7, 2024. https:\/\/mexiconewsdaily.com\/wellness\/psilocybin-from-magic-mushrooms-to-the-doctors-office\/"},{"key":"zoi261045r238","unstructured":"Main? D. Psilocybin, from magic mushrooms, eases anxiety and depression in cancer patients. Newsweek. December 16, 2016. Accessed November 7, 2024. https:\/\/www.proquest.com\/docview\/1847774029"},{"key":"zoi261045r239","unstructured":"Psilocybin, another lost opportunity for Mexico? ContentEngine. September 21, 2022. Accessed November 7, 2024. https:\/\/www.proquest.com\/docview\/2716944263"},{"key":"zoi261045r240","unstructured":"Psilocybin-assisted therapy reduces depressive symptoms in adults with cancer, depression: study. Asian News International. December 18, 2023. Accessed September 22, 2026. https:\/\/www.aninews.in\/news\/health\/psilocybin-assisted-therapy-reduces-depressive-symptoms-in-adults-with-cancer-depression-study20231218195421\/"},{"key":"zoi261045r242","unstructured":"Preliminary trial shows psilocybin reduces intensity, magnitude of migraines. PsychedelicNewsWire. August 14, 2023. Accessed November 7, 2024. https:\/\/rss.investorbrandnetwork.com\/pnw-full\/preliminary-trial-shows-psilocybin-reduces-intensity-magnitude-of-migraines\/"},{"key":"zoi261045r243","unstructured":"Mahindra? AS. Over 5 million Americans could benefit if psilocybin is approved for depression, finds study. Times Now. September 16, 2024. Accessed November 7, 2024. https:\/\/www.timesnownews.com\/health\/mental-health\/over-5-million-americans-could-benefit-if-psilocybin-is-approved-for-depression-finds-study-article-113379585"},{"key":"zoi261045r244","unstructured":"Oregon State University. Oregon State research helps provide scientific framework for psilocybin use in therapeutic settings. NewsRx. April 25, 2022. Accessed November 7, 2024. https:\/\/news.oregonstate.edu\/news\/oregon-state-research-helps-provide-scientific-framework-psilocybin-use-therapeutic-settings"},{"key":"zoi261045r245","unstructured":"Obesity enters the psychedelic panacea\u2019s sights. ContentEngine. November 25, 2022. Accessed November 7, 2024. https:\/\/www.proquest.com\/docview\/2740273221"},{"key":"zoi261045r246","unstructured":"New York University. Antianxiety and antidepressant effects from a single dose of psychedelic drug persist years later in cancer patients. ScienceDaily. January 31, 2020. Accessed November 7, 2024. https:\/\/www.sciencedaily.com\/releases\/2020\/01\/200128115423.htm"},{"key":"zoi261045r247","unstructured":"Syal? A. NIH-funded psychedelic trial will study whether hallucinogen can help smokers quit. NBC News. November 4, 2022. Accessed November 7, 2024. https:\/\/www.nbcnews.com\/health\/health-news\/nih-funded-psychedelic-trial-will-study-whether-hallucinogen-can-help-rcna53922"},{"key":"zoi261045r248","unstructured":"Ponieman? N. NIH director praises psychedelics\u2019 potential as therapeutic treatment, touts progress in access to cannabis for research. Benzinga. May 27, 2021. Accessed November 7, 2024. https:\/\/www.benzinga.com\/markets\/cannabis\/21\/05\/21309351\/nih-director-praises-psychedelics-potential-as-therapeutic-treatment-touts-progress-in-access-to"},{"key":"zoi261045r249","unstructured":"Krieger? L. New psychedelic-like drugs: all treatment, no trip? SiliconValley.com. December 12, 2023. Accessed November 7, 2024. https:\/\/www.siliconvalley.com\/2023\/12\/12\/new-psychedelic-like-drugs-all-treatment-no-trip\/"},{"key":"zoi261045r251","unstructured":"Fenster? JN. Mushroom therapy? Yale study to assess real-life benefits of psilocybin on mental health. CTInsider. May 29, 2024. Accessed November 7, 2024. https:\/\/www.ctinsider.com\/connecticut\/article\/ct-psilocybin-therapy-mushrooms-research-19474048.php"},{"key":"zoi261045r252","unstructured":"Rodriguez? NJ. Missouri: lawmaker files bill that would decriminalize psychedelics for therapeutic use. Benzinga. March 8, 2022. Accessed November 7, 2024. https:\/\/drupal-cloudfront.benzinga.com\/government\/22\/03\/26029793\/missouri-lawmaker-files-bill-that-would-decriminalize-psychedelics-for-therapeutic-use"},{"key":"zoi261045r253","doi-asserted-by":"crossref","unstructured":"Boehnke? KF. How cannabis and psilocybin might help some of the 50 million Americans who are experiencing chronic pain. The Conversation. May 10, 2024. Accessed November 7, 2024. https:\/\/theconversation.com\/how-cannabis-and-psilocybin-might-help-some-of-the-50-million-americans-who-are-experiencing-chronic-pain-225887","DOI":"10.64628\/AAI.pjrhwgred"},{"key":"zoi261045r254","unstructured":"Black Press Media Staff. Metchosin woman\u2019s trauma treatment could be trendsetting. Saanich News. December 7, 2020. Accessed November 7, 2024. https:\/\/www.saanichnews.com\/news\/metchosin-womans-trauma-treatment-could-be-trendsetting-293281"},{"key":"zoi261045r255","unstructured":"Donnini? A. Meet the London care providers fighting to prescribe psychedelic mushrooms. CBC News. June 9, 2023. Accessed November 7, 2024. https:\/\/www.cbc.ca\/news\/canada\/london\/meet-the-london-care-providers-fighting-to-prescribe-psychedelic-mushrooms-1.6863827"},{"key":"zoi261045r256","unstructured":"Mammoser? G. Mushrooms as medicine? psychedelics may be next breakthrough treatment. Healthline. February 12, 2019. Accessed November 7, 2024. https:\/\/healthline.com\/health-news\/benefits-of-medical-mushrooms"},{"key":"zoi261045r257","unstructured":"Legge? J. Magical medicine: BC cannabis farmers are ready to safely produce psilocybin. The Abbotsford News. July 27, 2022. Accessed November 7, 2024. https:\/\/abbynews.com\/2022\/07\/27\/magical-medicine-b-c-cannabis-farmers-are-ready-to-safely-produce-psilocybin\/"},{"key":"zoi261045r258","unstructured":"Diwan? P. Magic mushroomsN, LSD can treat anxiety and addictions. TopNews. May 28, 2015. Accessed November 7, 2024. https:\/\/global-factiva-com.libaccess.lib.mcmaster.ca\/hp\/printsavews.aspx?ppstype=Article&pp=Print&hc=Publicatio"},{"key":"zoi261045r262","unstructured":"Samenow D, Kung K, Ludwig R. State psychedelic regulation: Oregon and Colorado taking the lead. DLA Piper. January 11, 2023. Accessed February 11, 2026. https:\/\/www.dlapiper.com\/en-ca\/insights\/publications\/2023\/01\/state-psychedelic-regulation-oregon-and-colorado-taking-the-lead"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2855499\/madden_2026_oi_261045_1791898669.70476.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:30:34Z","timestamp":1792510234000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2855499"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":263,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.38843","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]}}}